Last reviewed · How we verify
Voltaren Topical Gel, 1%
Voltaren Topical Gel, 1% works by reducing inflammation and pain through the inhibition of prostaglandin synthesis.
Voltaren Topical Gel, 1% works by reducing inflammation and pain through the inhibition of prostaglandin synthesis. Used for Relief of pain, inflammation, and stiffness associated with osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
At a glance
| Generic name | Voltaren Topical Gel, 1% |
|---|---|
| Sponsor | Amneal Pharmaceuticals, LLC |
| Drug class | NSAID |
| Target | COX |
| Modality | Small molecule |
| Therapeutic area | Musculoskeletal |
| Phase | Phase 3 |
Mechanism of action
It achieves this by blocking the enzyme cyclooxygenase (COX), which is responsible for producing prostaglandins, leading to decreased inflammation and pain. This mechanism is similar to other nonsteroidal anti-inflammatory drugs (NSAIDs).
Approved indications
- Relief of pain, inflammation, and stiffness associated with osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis
Common side effects
- Skin irritation
- Allergic contact dermatitis
Key clinical trials
- Counterpain PXM Versus Diclofenac Versus Piroxicam (PHASE3)
- Effects of Photobiomodulation and Topical Diclofenac on Inflammation and Pain in Knee Osteoarthritis (EPIC-KO) (PHASE2)
- Comparison of Diclofenac Systemic Exposure From Two Different Products (AMZ001 and Diclofenac Diethylammonium 1.16% Gel) in Healthy Participants After Repeated Topical Administrations for 7 Days. (PHASE1)
- To Check Dermatological Safety of Test Products by 24 Hours Patch Testing (NA)
- Topical Diclofenac for Hand-Foot Syndrome Prevention in Colorectal and Gastric Cancer on Capecitabine (DICLO-HFS)
- Exercise vs. Topical Diclofenac vs. PRP (NA)
- Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Knee Pain Related to Osteoarthritis (PHASE2)
- Comparative Usability Evaluation of Sustained Acoustic Medicine (SAM) Devices and Topical Gel for OA Knee Pain (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Voltaren Topical Gel, 1% CI brief — competitive landscape report
- Voltaren Topical Gel, 1% updates RSS · CI watch RSS
- Amneal Pharmaceuticals, LLC portfolio CI